ReviewCells2026
Serotonin as a Regulator of Innate and Adaptive Immunity: Mechanisms and Clinical Relevance in Inflammatory Disease.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Serotonin (5-hydroxytryptamine, 5-HT) is traditionally considered a neurotransmitter, but most of the body's serotonin is peripheral and participates in vascular, hemostatic, inflammatory, and immune processes. This review summarizes current evidence on the role of peripheral serotonin in innate and adaptive immunity and evaluates its clinical relevance in inflammatory and immune-mediated diseases. The article synthesizes experimental and clinical data on serotonin sources, 5-HT receptors, SERT, serotonylation, and 5-HT-dependent regulation of neutrophils, monocytes/macrophages, mast cells, dendritic cells, T cells, and B cells. The reviewed data indicate that serotonin modulates leukocyte recruitment, platelet-immune interactions, NETosis, macrophage polarization, dendritic cell-T-cell communication, lymphocyte activation, vascular permeability, and tissue remodeling. Clinically, serotonergic mechanisms are implicated in sepsis, inflammatory bowel disease, autoimmune disorders, cardiovascular inflammation, thromboinflammation, and the tumor microenvironment. However, the direction of 5-HT effects is not uniform and depends on receptor subtype, cell type, local mediator concentration, disease stage, and tissue context. Serotonin should therefore be regarded as a context-dependent immunoregulatory mediator rather than an exclusively pro- or anti-inflammatory factor. Further studies are needed to standardize clinical measurements of serotonin and its metabolites and to define therapeutically relevant serotonergic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.